But biomarker enrichment and toxicity remain key for FX-909.
ApexOnco Front Page
Recent articles
The month saw the first commissioner's priority voucher approval in oncology.
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
Pfizer cans PF-08046045, but keeps PF-08046044 for now.
Blackstone follows Abingworth, but why?
The company will no longer initiate a head-to-head trial of safusidenib against Voranigo.
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
